Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications.
Eunjin HongAlan ShiPaul M BeringerPublished in: Expert opinion on drug metabolism & toxicology (2023)
Dosing recommendations for CFTR modulators with DDIs are relatively comprehensive; however, recommendations on timing of dosing transition of CFTR modulators when CYP3A inhibitors are initiated or discontinued is incomplete. Certain drug interactions may be managed by choosing an alternative treatment to avoid/minimize DDIs. Next generation CFTR modulator therapies under development are expected to provide increased activity with reduced DDI risk.